A call to action to safeguard affordable generic and biosimilar medicines
WASHINGTON (February 13, 2025) — The Association for Accessible Medicines today commented on the confirmation of Robert F. Kennedy Jr. as Secretary of the United States Department of Health and Human Services. The Senate voted today 52-48 to confirm Secretary Kennedy.
“Making America healthy and keeping America healthy depends on access to affordable, reliable medicine,” said John Murphy III, President and CEO of the Association for Accessible Medicines. “Generic medicines drive deflation in the healthcare system, making up more than 90% of all U.S. prescriptions but only 13% of spending. The current system is broken when generic manufacturers struggle to break even while bureaucracy and middlemen drive cost increases for patients and U.S. taxpayers. We look forward to working with Secretary Kennedy to fix this broken system and develop a sustainable market for generic and biosimilar medicines in the United States.”
View AAM 2025 Advocacy Priorities
For media inquiries, contact media@accessiblemeds.org.
About AAM
The Association for Accessible Medicines, your generics and biosimilars industry, is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. AAM represents the manufacturers of finished generic pharmaceuticals and biosimilars, manufacturers of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 13.1 percent of total drug spending.
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines, works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is the leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, government affairs, legal affairs, and regulatory policy. More information is available at biosimilarscouncil.org.
